vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $151.1M, roughly 1.9× STURM RUGER & CO INC). On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 3.6%). STURM RUGER & CO INC produced more free cash flow last quarter ($12.3M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
GH vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $151.1M |
| Net Profit | $-128.5M | — |
| Gross Margin | 64.6% | 17.8% |
| Operating Margin | -43.0% | 2.3% |
| Net Margin | -45.7% | — |
| Revenue YoY | 39.4% | 3.6% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $151.1M | ||
| Q3 25 | $265.2M | $126.8M | ||
| Q2 25 | $232.1M | $132.5M | ||
| Q1 25 | $203.5M | $135.7M | ||
| Q4 24 | $201.8M | $145.8M | ||
| Q3 24 | $191.5M | $122.3M | ||
| Q2 24 | $177.2M | $130.8M | ||
| Q1 24 | $168.5M | $136.8M |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $1.6M | ||
| Q2 25 | $-99.9M | $-17.2M | ||
| Q1 25 | $-95.2M | $7.8M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $4.7M | ||
| Q2 24 | $-102.6M | $8.3M | ||
| Q1 24 | $-115.0M | $7.1M |
| Q4 25 | 64.6% | 17.8% | ||
| Q3 25 | 64.7% | 15.1% | ||
| Q2 25 | 65.0% | 3.9% | ||
| Q1 25 | 63.3% | 22.0% | ||
| Q4 24 | 61.6% | 22.8% | ||
| Q3 24 | 61.1% | 18.5% | ||
| Q2 24 | 59.1% | 22.3% | ||
| Q1 24 | 61.2% | 21.5% |
| Q4 25 | -43.0% | 2.3% | ||
| Q3 25 | -37.3% | -2.7% | ||
| Q2 25 | -45.9% | -15.6% | ||
| Q1 25 | -54.6% | 6.2% | ||
| Q4 24 | -62.4% | 7.8% | ||
| Q3 24 | -61.3% | 3.1% | ||
| Q2 24 | -56.8% | 6.9% | ||
| Q1 24 | -59.2% | 5.5% |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 1.2% | ||
| Q2 25 | -43.0% | -13.0% | ||
| Q1 25 | -46.8% | 5.7% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 3.9% | ||
| Q2 24 | -57.9% | 6.3% | ||
| Q1 24 | -68.2% | 5.2% |
| Q4 25 | $-1.01 | $0.22 | ||
| Q3 25 | $-0.74 | $0.10 | ||
| Q2 25 | $-0.80 | $-1.05 | ||
| Q1 25 | $-0.77 | $0.46 | ||
| Q4 24 | $-0.90 | $0.62 | ||
| Q3 24 | $-0.88 | $0.28 | ||
| Q2 24 | $-0.84 | $0.47 | ||
| Q1 24 | $-0.94 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $92.5M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $283.8M |
| Total Assets | $2.0B | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $92.5M | ||
| Q3 25 | $580.0M | $80.8M | ||
| Q2 25 | $629.1M | $101.4M | ||
| Q1 25 | $698.6M | $108.3M | ||
| Q4 24 | $525.5M | $105.5M | ||
| Q3 24 | $585.0M | $96.0M | ||
| Q2 24 | $933.7M | $105.6M | ||
| Q1 24 | $1.0B | $115.3M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $283.8M | ||
| Q3 25 | $-354.5M | $279.6M | ||
| Q2 25 | $-305.5M | $289.3M | ||
| Q1 25 | $-250.8M | $321.5M | ||
| Q4 24 | $-139.6M | $319.6M | ||
| Q3 24 | $-60.1M | $314.9M | ||
| Q2 24 | $-1.6M | $321.5M | ||
| Q1 24 | $68.3M | $332.0M |
| Q4 25 | $2.0B | $342.0M | ||
| Q3 25 | $1.3B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.5B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.6B | $376.7M | ||
| Q1 24 | $1.7B | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $15.5M |
| Free Cash FlowOCF − Capex | $-54.2M | $12.3M |
| FCF MarginFCF / Revenue | -19.3% | 8.2% |
| Capex IntensityCapex / Revenue | 9.9% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $15.5M | ||
| Q3 25 | $-35.4M | $12.9M | ||
| Q2 25 | $-60.3M | $14.7M | ||
| Q1 25 | $-62.7M | $11.1M | ||
| Q4 24 | $-64.5M | $20.0M | ||
| Q3 24 | $-51.1M | $9.4M | ||
| Q2 24 | $-94.0M | $18.7M | ||
| Q1 24 | $-30.3M | $7.3M |
| Q4 25 | $-54.2M | $12.3M | ||
| Q3 25 | $-45.8M | $7.0M | ||
| Q2 25 | $-65.9M | $9.1M | ||
| Q1 25 | $-67.1M | $10.0M | ||
| Q4 24 | $-83.4M | $16.4M | ||
| Q3 24 | $-55.3M | $2.6M | ||
| Q2 24 | $-99.1M | $10.1M | ||
| Q1 24 | $-37.2M | $5.6M |
| Q4 25 | -19.3% | 8.2% | ||
| Q3 25 | -17.3% | 5.5% | ||
| Q2 25 | -28.4% | 6.9% | ||
| Q1 25 | -33.0% | 7.4% | ||
| Q4 24 | -41.3% | 11.2% | ||
| Q3 24 | -28.9% | 2.1% | ||
| Q2 24 | -55.9% | 7.7% | ||
| Q1 24 | -22.1% | 4.1% |
| Q4 25 | 9.9% | 2.1% | ||
| Q3 25 | 3.9% | 4.6% | ||
| Q2 25 | 2.4% | 4.2% | ||
| Q1 25 | 2.2% | 0.8% | ||
| Q4 24 | 9.4% | 2.5% | ||
| Q3 24 | 2.2% | 5.5% | ||
| Q2 24 | 2.9% | 6.6% | ||
| Q1 24 | 4.1% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
